Back to top
more

QIAGEN (QGEN)

(Delayed Data from NYSE)

$44.27 USD

44.27
1,818,546

+0.33 (0.75%)

Updated Jul 29, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

QIAGEN (QGEN) Catches Eye: Stock Jumps 9.9%

by Zacks Equity Research

QIAGEN (QGEN) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

QIAGEN (QGEN) Beats Q3 Earnings Estimates, Cuts Revenue View

by Zacks Equity Research

We are impressed with QIAGEN's (QGEN) year-over-year growth across majority of operating segments in Q3.

Qiagen (QGEN) Tops Q3 Earnings Estimates

by Zacks Equity Research

Qiagen (QGEN) delivered earnings and revenue surprises of 2.86% and -0.26%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Qiagen (QGEN) Q3 Earnings Preview: What's in the Cards?

by Zacks Equity Research

Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

QIAGEN (QGEN) Launches QIAseq FastSelect Technology Kits

by Zacks Equity Research

The launch of the kits is expected to bolster QIAGEN's (QGEN) Life Sciences Business Area

QIAGEN Down on Dim Q3 Prelim Sales, Startling CEO Departure

by Zacks Equity Research

If the dismal preliminary sales performance was not enough, then the news pertaining to QIAGEN's (QGEN) current CEO Peer M. Schatz's stepping down came as another huge blow.

QIAGEN Inks Deal With Illumina to Deliver NGS-Based IVD Kits

by Zacks Equity Research

QIAGEN (QGEN) aims to fast-track the adoption of NGS-based IVD test and improve patient outcomes through the new partnership deal.

Illumina (ILMN) Inks Deal to Commercialize NGS-Based IVD Kits

by Zacks Equity Research

Illumina (ILMN) aims to expand access to NGS-based IVD test kits and improve patient outcomes through the new partnership deal.

QIAGEN (QGEN) Hurt by Low QuantiFERON-TB Sales & FX Headwind

by Zacks Equity Research

Poor QuantiFERON-TB sales in Americas and an unfavourable currency translation affect QIAGEN's (QGEN) overall performance.

Qiagen (QGEN) Down 8.7% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

QIAGEN Posts QIAstat-Dx Gastrointestinal Panel Study Results

by Zacks Equity Research

The study outcome has been a major step for QIAGEN (QGEN) toward offering accurate diagnosis and treatment of gastroenteritis.

Inovio (INO) Q2 Earnings & Revenues Fall Shy of Estimates

by Zacks Equity Research

Inovio Pharmaceuticals (INO) disappoints with earnings and revenue miss in the second quarter. Shares depreciate in after-hours trading.

QIAGEN (QGEN) Misses Q2 Earnings Estimates, Lowers View

by Zacks Equity Research

QIAGEN (QGEN) registers revenue growth across majority of its geographies in Q2.

Qiagen (QGEN) Q2 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Qiagen (QGEN) delivered earnings and revenue surprises of -2.94% and -1.24%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Qiagen (QGEN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Inovio Ends Enrollment in Vulvar Dysplasia Study on VGX-3100

by Zacks Equity Research

Inovio (INO) closes enrollment in the phase II study, evaluating VGX-3100 for the treatment of HPV-related vulvar dysplasia.

Inovio Up on Enrollment Closure in Cervical Dysplasia Study

by Zacks Equity Research

Inovio (INO) concludes enrollment in the phase III study (REVEAL 1), which currently evaluates VGX-3100 for the treatment of cervical dysplasia, caused by HPV. Shares rally.

QIAGEN Inks Distribution Deal With Mckesson Medical-Surgical

by Zacks Equity Research

The distribution agreement will enable QIAGEN (QGEN) to expand reach in the healthcare market.

Here's Why You Should Hold on to QIAGEN (QGEN) Stock Now

by Zacks Equity Research

QIAGEN (QGEN) is enjoying investors' high confidence, courtesy of the QIAstat-Dx system.

QIAGEN-DiaSorin Union to Enhance QuantFERON for Lyme Disease

by Zacks Equity Research

QIAGEN (QGEN) expects multi-site clinical validations for this new system during 2020 Lyme disease season.

Qiagen (QGEN) Up 4% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

QIAGEN (QGEN) Launches PIK3CA Kit for Breast Cancer Patients

by Zacks Equity Research

QIAGEN's (QGEN) therascreen PIK3CA Kit is the first companion diagnostic test to have attained premarket approval from the FDA.

QIAGEN (QGEN) to Win U. N. Accolade for QuantiFERON-TB Access

by Zacks Equity Research

This acclaim marks a giant leap for QIAGEN (QGEN) in the field of tuberculosis diagnosis.

QIAGEN Partners Inovio to Develop Companion Diagnostics

by Zacks Equity Research

QIAGEN's (QGEN) Sample to Insight workflows and expertise in developing diagnostic solutions will aptly compliment Inovio regarding Precision Medicine in immuno-oncology.